Oncotarget

Research Papers:

Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation

Silvia Park, Kihyun Kim, Jun Ho Jang, Seok Jin Kim, Won Seog Kim and Chul Won Jung _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:59892-59901. https://doi.org/10.18632/oncotarget.10988

Metrics: PDF 1335 views  |   HTML 1996 views  |   ?  


Abstract

Silvia Park1, Kihyun Kim1, Jun Ho Jang1, Seok Jin Kim1, Won Seog Kim1, Chul Won Jung1

1Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University of School of Medicine, Seoul, Korea

Correspondence to:

Chul Won Jung, email: leukemia1@skku.edu

Keywords: cyclosporine, blood level, chronic graft versus host disease

Received: February 24, 2016    Accepted: June 30, 2016    Published: August 1, 2016

ABSTRACT

Introduction: It has rarely been studied that how the blood level of CsA affect the incidence of chronic GVHD after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Methods: A total of 183 patients who underwent allo-HSCT from an HLA-matched or haplo matched family donors between 2006 and 2014 were reviewed.

Results: The average monthly CsA blood concentration (CsAavr ,ng/ml) was calculated in each patient: 0-1, 1-2, and 2-3 months after allo-HSCT. CsAavr at the first month showed significant association with the occurrence of moderate to severe cGVHD in multivariate analysis adjusted for gender, age, total body irradiation, anti-thymocyte globulin, acute GVHD ≥ grade 2 and CsAavr levels of other periods. The risk of cGVHD development was lowest in patients with CsAavr of 200-250 ng/ml when compared to those with CsAavr of ≥ 250 or < 200 ng/ml (p=0.003).

Conclusions: CsA level between 200 and 250 mg/ml during the first month after transplantation was significantly associated with the decreased risk of moderate to severe cGVHD.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10988